Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sagent Pharmaceuticals has launched amiodarone HCl injection, USP, a class III antiarrhythmic indicated for the treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia.
Subscribe to our email newsletter
Sagent’s amiodarone HCl injection will be available immediately in 150mg/3 ml single dose prefilled syringes. Amiodarone prefilled syringes are manufactured for Sagent by Gland Pharma.
Amiodarone is said to be the eighth product introduced from Sagent’s pipeline of more than 200 products since the launch of the company’s first product in December 2007.
Jeffrey Yordon, CEO, founder, and chairman of the board of Sagent, said: “With our launch of the only multi-source, prefilled amiodarone syringe in the health care market, Sagent is making another essential product readily available to the emergency medicine community.”